Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.

BACKGROUND

There is an unmet need for effective therapies in pretreated advanced biliary tract cancer. We aimed to evaluate the efficacy of nanoliposomal irinotecan and fluorouracil plus leucovorin compared with fluorouracil plus leucovorin as second-line treatment for biliary tract cancer.

METHODS

NALIRICC was a multicentre, open-label, randomised, phase 2 trial done in 17 German centres for patients aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0-1, metastatic biliary tract cancer, and progression on gemcitabine-based therapy. Patients were randomly assigned (1:1) to receive intravenous infusions of nanoliposomal irinotecan (70 mg/m

FINDING

Between Dec 4, 2017, and Aug 2, 2021, 49 patients were randomly assigned to the nanoliposomal irinotecan group and 51 patients to the control group. Median age was 65 years (IQR 59-71); 45 (45%) of 100 patients were female. Median progression-free survival was 2·6 months (95% CI 1·7-3·6) in the nanoliposomal irinotecan group and 2·3 months (1·6-3·4) in the control group (hazard ratio [HR] 0·87 [0·56-1·35]). Median overall survival was 6·9 months (95% CI 5·3-10·6) in the nanoliposomal irinotecan group and 8·2 months (5·4-11·9) in the control group (HR 1·08 [0·68-1·72]). The objective response rate was 14% (95% CI 6-27; seven patients) in the nanoliposomal irinotecan group and 4% (1-14; two patients) in the control group. The most common grade 3 or worse adverse events in the nanoliposomal irinotecan group were neutropenia (eight [17%] of 48 vs none in the control group), diarrhoea (seven [15%] vs one [2%]), and nausea (four [8%] vs none). In the control group, the most common grade 3 or worse adverse events were cholangitis (four [8%] patients vs none in the nanoliposomal irinotecan group) and bile duct stenosis (four [8%] vs three [6%]). Treatment-related serious adverse events occurred in 16 (33%) patients in the nanoliposomal irinotecan group (grade 2-3 diarrhoea in five patients; one case each of abdominal infection, acute kidney injury, pancytopenia, increased blood bilirubin, colitis, dehydration, dyspnoea, infectious enterocolitis, ileus, oral mucositis, and nausea). One (2%) treatment-related serious adverse event occurred in the control group (worsening of general condition). Median duration until deterioration of global health status, characterised by the time from randomisation to the initial observation of a score decline exceeding 10 points, was 4·0 months (95% CI 2·2-not reached) in the nanoliposomal irinotecan group and 3·7 months (2·7-not reached) in the control group.

INTERPRETATION

The addition of nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve progression-free survival or overall survival and was associated with higher toxicity compared with fluorouracil plus leucovorin. Further research is necessary to define the role of irinotecan-based combinations in second-line treatment of biliary tract cancer.

FUNDING

Servier and AIO-Studien.

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests AV reports consulting fees, honoraria, and participation in advisory or data safety monitoring boards for AstraZeneca, Amgen, BeiGene, Boehringer Mannheim, Bristol Myers Squibb (BMS), BTG, Daichi-Sankyo, Eisai, Incyte, Ipsen, MSD, Pierre Fabre, Roche, Servier, Sirtex, Tahio, and Terumo; honoraria from GSK, Imaging Equipment (AAA), and Jiangsu Hengrui Medicines; and support for attending meetings or travel from Roche, MSD, and Astellas. SB reports consulting fees from Servier, AstraZeneca, BMS, and MSD; honoraria from Servier and MSD; and travel support from Lilly. DZ reports honoraria from AstraZeneca and Roche; and support for attending meetings or travel from Amgen and AstraZeneca. UG reports honoraria from AstraZeneca, Novartis, and Falk; participation in advisory or data safety monitoring boards for Amgen, Boehringer Ingelheim, MSD, BMS, Ipsen, Sanofi, and Celltrion; leadership or fiduciary roles for German Cancer Society (DKG) Board of Directors, Cancer Society of North Rhine Westphalia Chairman; and stock or stock options for Bayer and Biontech. TG reports grants or contracts from German Research Foundation (DFG), German Cancer Aid (Deutsche Krebshilfe), Gemeinsamer Bundesausschuss, Lilly, AstraZeneca, and Incyte; consulting fees from Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, FoundationMedicine, Lilly, MCI, MSD, Novartis, Roche, Sanofi Aventis, Servier, Deciphera, and Boehringer Ingelheim; honoraria from Amgen, BMS, Lilly, MSD, Novartis, Sanofi Aventis, Servier, and Roche; payment for expert testimony from Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and Daiichi Sankyo; participation in advisory or data safety monitoring boards for Bayer, BMS, Daiichi Sankyo, FoundationMedicine, Lilly, MCI, MSD, Novartis, Roche, Sanofi Aventis, and Servier; and leadership or fiduciary roles for AIO-Arbeitsgemeinschaft Internistische Onkologie, Board of Directors, and University Cancer Center Frankfurt. All other authors declare no competing interests.